BioMedPartners

ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of novel human immunomodulatory proteins aimed at enhancing cancer treatment and addressing autoimmune diseases. By focusing on next-generation therapeutics, ImmunOs aims to create drugs that not only exhibit direct anti-tumor effects but also remodel the tumor microenvironment. Additionally, the company is developing antibodies designed to block the activation of specific HLA molecules associated with autoimmune conditions. Through its innovative approach, ImmunOs Therapeutics seeks to improve the lives of patients suffering from serious diseases.

Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Their goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients.

Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.

Scenic Biotech B.V., founded in 2017 and based in Amsterdam, specializes in developing genomics and immunotherapy technologies aimed at addressing cancer and rare genetic diseases at their genetic roots. The company focuses on identifying disease-suppressing genes that serve as "off-switches" for GPCR signaling, enabling innovative therapeutic interventions. Scenic Biotech's approach involves unlocking genetic modifiers that can suppress or block the effects of disease-causing mutated genes. This technology allows for the rapid identification and validation of novel drug targets, facilitating the development of disease-modifying therapeutics that aim to improve the lives of patients suffering from severe conditions.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a specific microRNA, which serves as a molecular master switch regulating pathological changes in the heart due to stress or injury. Cardior Pharmaceuticals is committed to discovering and clinically validating innovative therapies that address the underlying causes of cardiac dysfunction, ultimately striving to improve patients' health and quality of life.

Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address significant unmet medical needs, particularly in autoimmune diseases, allergies, and anti-drug antibodies. The company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological processes. This approach targets liver sinusoidal endothelial cells to promote tolerance against blood-borne antigens. Topas is advancing several clinical-stage programs, with its lead candidate, TPM203, currently in clinical testing for pemphigus vulgaris, an orphan disease. Other therapeutic programs under development include treatments for celiac disease, Type 1 diabetes, and multiple sclerosis. The company has established research collaborations with Eli Lilly and Company and Boehringer Ingelheim to enhance its capabilities in antigen-specific tolerance induction and anti-drug antibodies, respectively. Topas Therapeutics was incorporated in 2013 and is dedicated to finding innovative solutions for chronic immunological conditions.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.

Noema Pharma is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address the most disabling symptoms associated with conditions such as Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By prioritizing patient needs, Noema Pharma seeks to create effective treatments that significantly improve the quality of life for individuals suffering from these challenging conditions.

Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address significant unmet medical needs, particularly in autoimmune diseases, allergies, and anti-drug antibodies. The company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological processes. This approach targets liver sinusoidal endothelial cells to promote tolerance against blood-borne antigens. Topas is advancing several clinical-stage programs, with its lead candidate, TPM203, currently in clinical testing for pemphigus vulgaris, an orphan disease. Other therapeutic programs under development include treatments for celiac disease, Type 1 diabetes, and multiple sclerosis. The company has established research collaborations with Eli Lilly and Company and Boehringer Ingelheim to enhance its capabilities in antigen-specific tolerance induction and anti-drug antibodies, respectively. Topas Therapeutics was incorporated in 2013 and is dedicated to finding innovative solutions for chronic immunological conditions.

Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Their goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients.

TOLREMO therapeutics AG, a biotechnology company, develops drug discovery engine and therapies to patients with cancer. The company was incorporated in 2017 and is based in Muttenz, Switzerland.

Azafaros B.V. is a Netherlands-based company focused on developing therapeutic agents for the treatment of rare metabolic disorders, specifically lysosomal storage disorders (LSDs). The company specializes in the oral administration of aza-sugar compounds, which were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros. These innovative agents aim to address key disease pathways by targeting the metabolism of glycosphingolipids and are designed to have a dual mode of action that can potentially improve patient outcomes. Through its research and development efforts, Azafaros seeks to provide effective treatments that can significantly enhance the lives of those affected by these severe inherited diseases.

Aleva Neurotherapeutics SA, founded in 2008 and based in Lausanne, Switzerland, specializes in the development of advanced implantable deep brain stimulation (DBS) systems. The company's product lineup includes directSTIM, an intelligent directional electrode designed to enhance the precision of electrical stimulation, and spiderSTIM, a diagnostic system that maps three-dimensional areas in brain targets to improve surgical outcomes. Additionally, Aleva is working on cortiSTIM, a device for cortical stimulation. Utilizing microelectromechanical systems (MEMS) technology, Aleva's devices aim to optimize existing therapies and enable the targeting of new brain areas, facilitating faster and more accurate surgical placements. The company focuses on treating neurological conditions such as Parkinson's disease and essential tremors. Aleva has successfully completed acute clinical trials for its products and is ISO13485 certified, reflecting its commitment to quality standards in medical device manufacturing. To date, Aleva has raised significant funding from various investors to support its ongoing development efforts.

ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of novel human immunomodulatory proteins aimed at enhancing cancer treatment and addressing autoimmune diseases. By focusing on next-generation therapeutics, ImmunOs aims to create drugs that not only exhibit direct anti-tumor effects but also remodel the tumor microenvironment. Additionally, the company is developing antibodies designed to block the activation of specific HLA molecules associated with autoimmune conditions. Through its innovative approach, ImmunOs Therapeutics seeks to improve the lives of patients suffering from serious diseases.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.

Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.

Amal Therapeutics SA is a biotech company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company focuses on the research and development of therapeutic vaccines for oncology, utilizing its proprietary cell penetrating peptide platform. Amal Therapeutics aims to create innovative therapeutic cancer vaccines and immunotherapies to enhance treatment options for cancer patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

TOLREMO therapeutics AG, a biotechnology company, develops drug discovery engine and therapies to patients with cancer. The company was incorporated in 2017 and is based in Muttenz, Switzerland.

TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.

Miracor Medical is a medical device company that specializes in developing solutions for severe cardiac diseases. Founded in 2008 and headquartered in Awans, Belgium, the company focuses on the PiCSO Impulse System, a pressure-controlled intermittent coronary sinus occlusion device. This system is designed to assist cardiac surgeons in treating patients with myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. By improving microvascular perfusion through the coronary sinus, the PiCSO Impulse System aims to reduce infarct size and enhance cardiac function, potentially lowering the risk of heart failure following acute myocardial infarction.

Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company's key platforms, Vaxwave and TheraT, aim to elicit robust immune responses, including high levels of neutralizing antibodies and T cells, which are often lacking in traditional therapies. Hookipa's product pipeline features HB-101, a vaccine targeting cytomegalovirus, and HB-201 and HB-202, which are in preclinical studies for human papillomavirus-positive cancers. Additionally, the company is collaborating with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and headquartered in New York, Hookipa Pharma aims to transform the field of immunotherapy through its innovative approaches.

Amal Therapeutics SA is a biotech company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company focuses on the research and development of therapeutic vaccines for oncology, utilizing its proprietary cell penetrating peptide platform. Amal Therapeutics aims to create innovative therapeutic cancer vaccines and immunotherapies to enhance treatment options for cancer patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a specific microRNA, which serves as a molecular master switch regulating pathological changes in the heart due to stress or injury. Cardior Pharmaceuticals is committed to discovering and clinically validating innovative therapies that address the underlying causes of cardiac dysfunction, ultimately striving to improve patients' health and quality of life.

Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company's key platforms, Vaxwave and TheraT, aim to elicit robust immune responses, including high levels of neutralizing antibodies and T cells, which are often lacking in traditional therapies. Hookipa's product pipeline features HB-101, a vaccine targeting cytomegalovirus, and HB-201 and HB-202, which are in preclinical studies for human papillomavirus-positive cancers. Additionally, the company is collaborating with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and headquartered in New York, Hookipa Pharma aims to transform the field of immunotherapy through its innovative approaches.

Miracor Medical is a medical device company that specializes in developing solutions for severe cardiac diseases. Founded in 2008 and headquartered in Awans, Belgium, the company focuses on the PiCSO Impulse System, a pressure-controlled intermittent coronary sinus occlusion device. This system is designed to assist cardiac surgeons in treating patients with myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. By improving microvascular perfusion through the coronary sinus, the PiCSO Impulse System aims to reduce infarct size and enhance cardiac function, potentially lowering the risk of heart failure following acute myocardial infarction.

Aleva Neurotherapeutics SA, founded in 2008 and based in Lausanne, Switzerland, specializes in the development of advanced implantable deep brain stimulation (DBS) systems. The company's product lineup includes directSTIM, an intelligent directional electrode designed to enhance the precision of electrical stimulation, and spiderSTIM, a diagnostic system that maps three-dimensional areas in brain targets to improve surgical outcomes. Additionally, Aleva is working on cortiSTIM, a device for cortical stimulation. Utilizing microelectromechanical systems (MEMS) technology, Aleva's devices aim to optimize existing therapies and enable the targeting of new brain areas, facilitating faster and more accurate surgical placements. The company focuses on treating neurological conditions such as Parkinson's disease and essential tremors. Aleva has successfully completed acute clinical trials for its products and is ISO13485 certified, reflecting its commitment to quality standards in medical device manufacturing. To date, Aleva has raised significant funding from various investors to support its ongoing development efforts.

Anergis SA is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, focused on developing allergy vaccines utilizing its proprietary technology of Contiguous Overlapping Peptides for rapid desensitization. Founded in 2001, Anergis specializes in immunotherapy targeting common allergens, including birch pollen, ragweed pollen, and house dust mites. The company's approach aims to provide long-term relief for allergy sufferers by offering a treatment that reduces the duration of therapy while effectively modifying the underlying allergic response. Anergis is dedicated to improving the quality of life for patients dealing with allergies through innovative medical solutions.

Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.

Miracor Medical is a medical device company that specializes in developing solutions for severe cardiac diseases. Founded in 2008 and headquartered in Awans, Belgium, the company focuses on the PiCSO Impulse System, a pressure-controlled intermittent coronary sinus occlusion device. This system is designed to assist cardiac surgeons in treating patients with myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. By improving microvascular perfusion through the coronary sinus, the PiCSO Impulse System aims to reduce infarct size and enhance cardiac function, potentially lowering the risk of heart failure following acute myocardial infarction.

Genkyotex SA is a biopharmaceutical company based in Labège, France, focusing on the development of innovative oral small molecule therapies that selectively inhibit NOX enzymes implicated in various disease processes. The company's lead candidate, GKT831, is a NOX1 and NOX4 inhibitor undergoing Phase II clinical trials for primary biliary cholangitis, a fibrotic orphan disease, and type 1 diabetes with kidney complications. In addition, Genkyotex is advancing GKT771, a preclinical NOX1 inhibitor aimed at addressing pain processing and inflammation. The company also holds a license agreement with Serum Institute of India Ltd. for GTL003, an antigen for developing multivalent combination vaccines against infectious diseases. Genkyotex's technology is designed to treat oxygen-radical mediated acute and chronic diseases, offering improved specificity and safety compared to existing antioxidant therapies, and targets cardiovascular, metabolic, and neurodegenerative conditions. Founded in 2006, Genkyotex is committed to enhancing patient outcomes through its research and development initiatives.

Anergis SA is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, focused on developing allergy vaccines utilizing its proprietary technology of Contiguous Overlapping Peptides for rapid desensitization. Founded in 2001, Anergis specializes in immunotherapy targeting common allergens, including birch pollen, ragweed pollen, and house dust mites. The company's approach aims to provide long-term relief for allergy sufferers by offering a treatment that reduces the duration of therapy while effectively modifying the underlying allergic response. Anergis is dedicated to improving the quality of life for patients dealing with allergies through innovative medical solutions.

AYOXXA Biosystems GmbH is a biotechnology company based in Cologne, Germany, with additional offices in Singapore and Boston, Massachusetts. Founded in 2010, AYOXXA specializes in life science tools, particularly through its proprietary technology platform for multiplexed protein analysis. The company has developed an innovative biochip technology that enables the simultaneous measurement of multiple protein markers associated with various health conditions, including cancer, allergies, cardiovascular diseases, and infectious diseases. AYOXXA's platform utilizes an in-situ encoded bead array, facilitating the identification and quantification of proteins and biomolecular analytes. This advanced approach to biomarker analysis positions AYOXXA at the forefront of diagnostic technology, allowing for comprehensive testing in a single assay.

Curetis N.V. is a commercial-stage molecular diagnostics company based in Holzgerlingen, Germany, specializing in solutions for severe infectious diseases. The company develops and manufactures a range of molecular microbiology products aimed at detecting various pathogens, including bacteria and fungi, as well as identifying genetic markers for antimicrobial resistance. Key offerings include the Unyvero L4 Lysator for sample pre-processing, the Unyvero A50 Analyzer, and the Unyvero C8 Cockpit, which serves as a control panel for these devices. Curetis also provides Unyvero Application Cartridges for syndromic infectious disease testing and the ARES AMR Database, which compiles data on antimicrobial resistance genetics. Its tests cover multiple infections, including pneumonia and urinary tract infections. Founded in 2007, Curetis has established strategic partnerships with companies like MGI Tech Co. Ltd. and Qiagen N.V., enhancing its capabilities in the molecular diagnostics market.

Humedics GmbH, founded in 2009 and based in Berlin, Germany, specializes in the development of a breath analysis device designed to assess liver function in patients suffering from liver failure. The company's key product, the LiMAx test, is a diagnostic system that includes a medical device, breath masks, and a diagnostic drug, enabling clinicians to quantitatively evaluate individual liver function. This technology supports various applications, such as assessing liver function before and after transplantation, planning liver surgeries, and evaluating conditions like liver cirrhosis. By providing rapid and precise measurements at the bedside, LiMAx facilitates informed decision-making for tailored medical treatments, thereby enhancing patient outcomes. The company has successfully used its technology with thousands of patients and is focused on expanding its global operations.

ImevaX GmbH is a biopharmaceutical company based in Munich, Germany, established in 2014. The company specializes in developing targeted vaccines to address chronic and nosocomial infections, with a particular focus on immune evasion factors employed by various pathogens. Its lead candidate, IMX 101, is designed to combat Helicobacter pylori, a bacterium responsible for stomach ulcers and gastric cancer in humans. ImevaX's research highlights the role of specific bacterial factors that enable H. pylori to evade the host immune response, prompting further investigation into similar mechanisms in other infectious pathogens. The company's efforts aim to enhance treatment options and improve health outcomes for patients suffering from these persistent infections.

At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.

Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.

Anergis SA is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, focused on developing allergy vaccines utilizing its proprietary technology of Contiguous Overlapping Peptides for rapid desensitization. Founded in 2001, Anergis specializes in immunotherapy targeting common allergens, including birch pollen, ragweed pollen, and house dust mites. The company's approach aims to provide long-term relief for allergy sufferers by offering a treatment that reduces the duration of therapy while effectively modifying the underlying allergic response. Anergis is dedicated to improving the quality of life for patients dealing with allergies through innovative medical solutions.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company's key platforms, Vaxwave and TheraT, aim to elicit robust immune responses, including high levels of neutralizing antibodies and T cells, which are often lacking in traditional therapies. Hookipa's product pipeline features HB-101, a vaccine targeting cytomegalovirus, and HB-201 and HB-202, which are in preclinical studies for human papillomavirus-positive cancers. Additionally, the company is collaborating with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and headquartered in New York, Hookipa Pharma aims to transform the field of immunotherapy through its innovative approaches.

Middle Peak Medical is a privately held medical device company dedicated to developing innovative solutions for mitral valve disease. The company focuses on creating a proprietary device designed to address unmet needs in treating mitral valve regurgitation. This novel technology aims to restore mitral valve competence in both functional and degenerative conditions by providing a new posterior surface for the anterior leaflet to seal properly. The device is applicable in both percutaneous catheter-based interventions and minimally invasive or open-heart cardiac surgeries, positioning Middle Peak Medical as a key player in advancing treatment options for patients with mitral valve disorders.

SuppreMol is a private biotechnology company that specializes in developing therapeutics for autoimmune and allergic diseases. The company is dedicated to creating innovative treatments aimed at addressing the underlying causes of these disorders, rather than just alleviating their symptoms. SuppreMol's research focuses on soluble Fc-gamma receptors, which are recombinant autologous therapeutic proteins designed to possess specific immunoregulatory properties. This approach has the potential to advance the treatment landscape for individuals suffering from autoimmune conditions, offering new hope for more effective and long-lasting solutions.

At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Aleva Neurotherapeutics SA, founded in 2008 and based in Lausanne, Switzerland, specializes in the development of advanced implantable deep brain stimulation (DBS) systems. The company's product lineup includes directSTIM, an intelligent directional electrode designed to enhance the precision of electrical stimulation, and spiderSTIM, a diagnostic system that maps three-dimensional areas in brain targets to improve surgical outcomes. Additionally, Aleva is working on cortiSTIM, a device for cortical stimulation. Utilizing microelectromechanical systems (MEMS) technology, Aleva's devices aim to optimize existing therapies and enable the targeting of new brain areas, facilitating faster and more accurate surgical placements. The company focuses on treating neurological conditions such as Parkinson's disease and essential tremors. Aleva has successfully completed acute clinical trials for its products and is ISO13485 certified, reflecting its commitment to quality standards in medical device manufacturing. To date, Aleva has raised significant funding from various investors to support its ongoing development efforts.

Aleva Neurotherapeutics SA, founded in 2008 and based in Lausanne, Switzerland, specializes in the development of advanced implantable deep brain stimulation (DBS) systems. The company's product lineup includes directSTIM, an intelligent directional electrode designed to enhance the precision of electrical stimulation, and spiderSTIM, a diagnostic system that maps three-dimensional areas in brain targets to improve surgical outcomes. Additionally, Aleva is working on cortiSTIM, a device for cortical stimulation. Utilizing microelectromechanical systems (MEMS) technology, Aleva's devices aim to optimize existing therapies and enable the targeting of new brain areas, facilitating faster and more accurate surgical placements. The company focuses on treating neurological conditions such as Parkinson's disease and essential tremors. Aleva has successfully completed acute clinical trials for its products and is ISO13485 certified, reflecting its commitment to quality standards in medical device manufacturing. To date, Aleva has raised significant funding from various investors to support its ongoing development efforts.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Anergis SA is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, focused on developing allergy vaccines utilizing its proprietary technology of Contiguous Overlapping Peptides for rapid desensitization. Founded in 2001, Anergis specializes in immunotherapy targeting common allergens, including birch pollen, ragweed pollen, and house dust mites. The company's approach aims to provide long-term relief for allergy sufferers by offering a treatment that reduces the duration of therapy while effectively modifying the underlying allergic response. Anergis is dedicated to improving the quality of life for patients dealing with allergies through innovative medical solutions.

Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.

Activaero GmbH is a drug delivery company focused on the research, development, manufacture, and marketing of controlled breathing technologies for inhaled therapeutic agents. Based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero offers a range of innovative products, including AKITA, a controlled breathing device equipped with smart card technology, and Watchhaler, designed specifically for children requiring inhaled medication. The company's technologies aim to ensure efficient and safe drug deposition in the lungs, addressing severe respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and idiopathic pulmonary fibrosis. Activaero also provides AKITA² for clinical trial settings and LimiX, a flow limitation valve that regulates flow rates. Additionally, the company offers measurement and diagnostic technologies for laboratory use and contract development services for clinical trials. Its products are marketed through a network of distributors. Founded in 2004, Activaero is dedicated to improving therapy outcomes for patients with lung diseases.

Vaximm specializes in developing active immunotherapies, specifically oral T-cell vaccines, for cancer patients. The company's lead product candidate, VXM01, aims to target the tumor vasculature, a critical component for tumor growth beyond microscopic size. Vaximm's innovative approach utilizes modified attenuated bacteria as first-in-class oral T-cell activators, allowing for flexible targeting of various cancer-related antigens. Preclinical studies have demonstrated significant anti-tumor activity, and Vaximm is poised to advance into human clinical trials, marking a significant step in offering advanced treatment options for cancer patients.

SuppreMol is a private biotechnology company that specializes in developing therapeutics for autoimmune and allergic diseases. The company is dedicated to creating innovative treatments aimed at addressing the underlying causes of these disorders, rather than just alleviating their symptoms. SuppreMol's research focuses on soluble Fc-gamma receptors, which are recombinant autologous therapeutic proteins designed to possess specific immunoregulatory properties. This approach has the potential to advance the treatment landscape for individuals suffering from autoimmune conditions, offering new hope for more effective and long-lasting solutions.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Evolva Holding SA is a biotechnology company based in Switzerland that specializes in discovering, developing, and commercializing innovative ingredients for various sectors, including food, nutrition, personal healthcare, and agriculture. Founded in 2004, the company leverages a proprietary synthetic biology technology platform to create high-quality ingredients that mirror the properties of natural products while eliminating their drawbacks. Evolva's product portfolio includes branded ingredients like Veri-te Resveratrol, used for age-related health, and EverSweet Stevia, a natural sweetener. Additionally, the company offers Nootkashield for pest control, EveNootkatone for flavor and fragrance applications, and EveValencene, a citrus flavoring. Evolva serves diverse markets, including nutrition, flavors and fragrances, animal health, personal care, and pharmaceuticals, both developing its own products and collaborating with other industry players.

Curetis N.V. is a commercial-stage molecular diagnostics company based in Holzgerlingen, Germany, specializing in solutions for severe infectious diseases. The company develops and manufactures a range of molecular microbiology products aimed at detecting various pathogens, including bacteria and fungi, as well as identifying genetic markers for antimicrobial resistance. Key offerings include the Unyvero L4 Lysator for sample pre-processing, the Unyvero A50 Analyzer, and the Unyvero C8 Cockpit, which serves as a control panel for these devices. Curetis also provides Unyvero Application Cartridges for syndromic infectious disease testing and the ARES AMR Database, which compiles data on antimicrobial resistance genetics. Its tests cover multiple infections, including pneumonia and urinary tract infections. Founded in 2007, Curetis has established strategic partnerships with companies like MGI Tech Co. Ltd. and Qiagen N.V., enhancing its capabilities in the molecular diagnostics market.

Activaero GmbH is a drug delivery company focused on the research, development, manufacture, and marketing of controlled breathing technologies for inhaled therapeutic agents. Based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero offers a range of innovative products, including AKITA, a controlled breathing device equipped with smart card technology, and Watchhaler, designed specifically for children requiring inhaled medication. The company's technologies aim to ensure efficient and safe drug deposition in the lungs, addressing severe respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and idiopathic pulmonary fibrosis. Activaero also provides AKITA² for clinical trial settings and LimiX, a flow limitation valve that regulates flow rates. Additionally, the company offers measurement and diagnostic technologies for laboratory use and contract development services for clinical trials. Its products are marketed through a network of distributors. Founded in 2004, Activaero is dedicated to improving therapy outcomes for patients with lung diseases.

Evolva Holding SA is a biotechnology company based in Switzerland that specializes in discovering, developing, and commercializing innovative ingredients for various sectors, including food, nutrition, personal healthcare, and agriculture. Founded in 2004, the company leverages a proprietary synthetic biology technology platform to create high-quality ingredients that mirror the properties of natural products while eliminating their drawbacks. Evolva's product portfolio includes branded ingredients like Veri-te Resveratrol, used for age-related health, and EverSweet Stevia, a natural sweetener. Additionally, the company offers Nootkashield for pest control, EveNootkatone for flavor and fragrance applications, and EveValencene, a citrus flavoring. Evolva serves diverse markets, including nutrition, flavors and fragrances, animal health, personal care, and pharmaceuticals, both developing its own products and collaborating with other industry players.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Lumavita AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development and commercialization of innovative anti-infectives aimed at women's health. Founded in 2008, the company offers products such as FemiFect, an antibiotic designed to treat infections associated with vaginitis caused by bacteria, fungi, and protozoa, and SPK-601, which targets human papillomavirus (HPV) and herpes simplex virus (HSV). Lumavita markets its products through various distributors, positioning itself within the expanding biopharmaceutical sector in Switzerland. The company was previously known as Shogoo Pharmaceuticals, AG before rebranding in December 2007 and operates as a subsidiary of Shogoo Pharmaceuticals KK.

ESBATech, founded in 1998 as a spin-off from the University of Zurich, specializes in the development of fully human antibody fragments for therapeutic purposes. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant diseases. ESBATech aims to deliver high concentrations of these therapeutic antibody fragments to specific sites while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions. In addition to its innovative antibody development, the company offers drug development services and manages various development programs, positioning itself as a leader in the field of targeted therapies.

SuppreMol is a private biotechnology company that specializes in developing therapeutics for autoimmune and allergic diseases. The company is dedicated to creating innovative treatments aimed at addressing the underlying causes of these disorders, rather than just alleviating their symptoms. SuppreMol's research focuses on soluble Fc-gamma receptors, which are recombinant autologous therapeutic proteins designed to possess specific immunoregulatory properties. This approach has the potential to advance the treatment landscape for individuals suffering from autoimmune conditions, offering new hope for more effective and long-lasting solutions.

Vivendy Therapeutics Ltd. is dedicated to developing enzyme replacement therapies for Morbus Morquio, a rare lysosomal storage disease caused by a genetic deficiency. Founded in 2006 and headquartered in Basel, Switzerland, the company has created a specialized recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is engineered to enhance enzyme activity. This modification significantly improves the efficacy of the therapy for MPS IVA, aiming to provide better treatment options for patients affected by this condition.

Idiag AG is a Swiss company that specializes in designing, manufacturing, and marketing healthcare equipment aimed at enhancing health and performance. Among its notable products are SpinalMouse, a tool for assessing back conditions; STMedical, a respiratory therapy device; SpiroTiger, which focuses on respiratory training; and Biacorpus RX 4000, used for bio-electrical impedance analysis to evaluate body composition. The company also offers weight management solutions like Fitmate and various spinal analysis and therapy products, including ValedoShape and ValedoMotion. Idiag serves a diverse clientele, including doctors, physiotherapists, athletes, clinics, and health centers, distributing its products through dealers in Switzerland, Germany, and internationally. Established in 1993 and headquartered in Fehraltorf, Switzerland, Idiag aims to bridge research, development, and market readiness for innovative medical technologies, providing a platform for universities and innovation centers to bring their concepts to market.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Okairos AG is a biopharmaceutical company that specializes in the discovery and development of genetic T-cell vaccines, with a significant focus on combating the hepatitis C virus. The company is also involved in providing health and allied services. Headquartered in Basel, Switzerland, Okairos operates in Rome and Naples, Italy. It has expertise in gene delivery technologies and scalable viral-vector manufacturing processes, which facilitate the advancement of vaccines and advanced therapies. By utilizing state-of-the-art GMP facilities, Okairos supports biotech companies in transitioning their genetic vaccines and medicinal products from preclinical stages to commercial readiness.

Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company that develops and commercializes innovative medicines for rare neuromuscular and pulmonary diseases, addressing high unmet medical needs. The company focuses on a product portfolio for Duchenne muscular dystrophy (DMD), including late-stage candidates such as Puldysa (idebenone) and vamorolone, which aim to treat patients regardless of their specific mutations, disease stage, or age. Additionally, Santhera's clinical pipeline includes lonodelestat (POL6014) for cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy for congenital muscular dystrophies. The company also out-licenses the rights to its approved product Raxone (idebenone) for Leber's hereditary optic neuropathy outside North America and has collaborated with Cold Spring Harbor Laboratory to explore lonodelestat as a potential treatment for COVID-19-related acute respiratory distress syndrome. Headquartered in Pratteln, Switzerland, Santhera primarily generates its revenue from the European Union.

ESBATech, founded in 1998 as a spin-off from the University of Zurich, specializes in the development of fully human antibody fragments for therapeutic purposes. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant diseases. ESBATech aims to deliver high concentrations of these therapeutic antibody fragments to specific sites while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions. In addition to its innovative antibody development, the company offers drug development services and manages various development programs, positioning itself as a leader in the field of targeted therapies.

EyeSense AG develops ophthalmic diagnostic systems focusing on glucose testing for diabetic patients. They make blood glucose control easier and pain-free through innovative monitoring devices.

Bioheart, Inc. is dedicated to advancing the field of regenerative medicine by offering the highest quality technology, cellular treatments and training. Specific to biotechnology, Bioheart, Inc. specializes in the discovery, development and commercialization of autologous cellular therapies that treat a wide variety of degenerative diseases. Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry by delivering stem cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, chronic and acute heart damage, peripheral vascular disease and other issues. Bioheart's goals are to improve a patient’s quality of life by regenerating their damaged tissue, when possible, and by reducing health care costs and hospitalizations. Bioheart’s leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.

Spinal Cord Therapeutics GmbH develops treatments for spinal cord injury. Spinal Cord Therapeutics focuses on the treatment of traumatic injury to the central nervous system.

Dolthera GmbH is a biopharmaceutical company that is developing an innovative class of nucleic-acid-based anti-inflammatory drugs. These drugs, based on oligonucleotides that act as decoys for disease-related transcription factors are all directed against biologically validated targets in major chronic diseases with high unmet medical need. With this business concept and the underlying patent-protected technologies, AVONTEC won in 2003 the prestigious German Founders Award that is backed by McKinsey & Company. Initially, the Company has chosen to focus its patented technology on chronic inflammatory respiratory system and skin diseases. AVONTEC currently has five programs in respiratory disease, skin disease, transplant rejection, cardiovascular disease and autoimmune disease under development. All these indications represent areas with high unmet medical need and strong commercial potential.

Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies for patients with heart valve diseases, particularly aortic valve stenosis. The company focuses on enhancing patient care and safety by providing simple and accurate solutions for heart valve replacement. Its proprietary Acurate Aortic Valve Replacement System features a distinctive self-positioning design, which facilitates easy implant positioning and alignment, thereby improving the overall ease of use for healthcare providers. Through its advanced transcatheter aortic valve implantation devices, Symetis aims to address severe cardiac valve conditions and enhance treatment options within the healthcare industry.

4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology. Its technology platform Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating human antibody libraries expressed in mammalian B-lineage lymphocytes. The company also develops preclinical checkpoint antibody programs targeting GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3. 4-Antibody AG was founded in 2002 and is based in Basel, Switzerland.

CareX SA is a biopharmaceutical company that develops novel treatments for metabolic and immune system disorders which includes diabetes and obesity. The company focuses on metabolic syndrome, a cluster of inter-related disorders of the body’s metabolism, including high blood pressure, high insulin levels, excess body weight, and abnormal cholesterol levels, that exposes individuals to the development of type 2 diabetes, heart diseases, and strokes. CareX SA is a France-based company that was founded in 2001 and the company was acquired by 7TM Pharma on May 24, 2006.

Roche Glycart develops antibody drug candidates, which include GA101, a humanized anti-CD20 monoclonal antibody to increase direct- and immune-mediated target cell death; and GA201, a humanized glycoengineered antibody for solid tumors.

Thommen Medical is a medical device company that specializes in the development, production, and sale of dental implants branded as SPI (Swiss Precision Implant). The company focuses on creating innovative and precisely designed implant systems that enhance patient comfort during surgical procedures and ensure long-term stability of the implants. Thommen Medical also offers biomaterial solutions for bone and tissue regeneration, collaborating with leading scientific and dental clinicians to improve the effectiveness and usability of its products. Through its commitment to design excellence and innovation, Thommen Medical aims to achieve optimal success for its clients in the field of dental implants.

ESBATech, founded in 1998 as a spin-off from the University of Zurich, specializes in the development of fully human antibody fragments for therapeutic purposes. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant diseases. ESBATech aims to deliver high concentrations of these therapeutic antibody fragments to specific sites while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions. In addition to its innovative antibody development, the company offers drug development services and manages various development programs, positioning itself as a leader in the field of targeted therapies.